<DOC>
	<DOCNO>NCT00002509</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining peripheral stem cell transplantation combination drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness high-dose combination chemotherapy follow peripheral stem cell transplantation autologous bone marrow transplantation woman stage II breast cancer eight positive axillary lymph node woman stage III metastatic breast cancer .</brief_summary>
	<brief_title>High-Dose Combination Chemotherapy Followed Peripheral Stem Cell Transplantation Treating Patients With Poor-Prognosis Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Investigate curative potential high-dose cyclophosphamide , etoposide , carboplatin follow autologous stem cell rescue woman breast cancer consider incurable conventional therapy . II . Observe overall response rate , survival rate , toxicity associate regimen . OUTLINE : Prior therapy , patient undergo collection peripheral blood stem cell ( PBSC ) another protocol ; patient marrow involvement undergo PBSC harvest , others may also undergo bone marrow harvest . All patient receive cyclophosphamide , etoposide , carboplatin 4 consecutive day , follow 3 day later PBSC bone marrow granulocyte colony-stimulating factor . Patients follow duration remission survival . PROJECTED ACCRUAL : 100-200 patient enter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive ( stage IIIV ) carcinoma breast 8 positive axillary node require stage II disease Chemotherapyresponsive disease require patient measurable evaluable disease Partial complete response 3 course standard cyclophosphamide/doxorubicin/fluorouracil ( CAF ) , patient CAF , cyclophosphamide/methotrexate/fluorouracil ( CMF ) 3month course standard mitomycin/vinblastine paclitaxel acceptable patient clearly resistant CAF CMF Visceral response despite progression bone consider individual basis Patients evidence disease may enter without evidence chemotherapy response Resectable disease must surgically remove prior transplantation Hormone receptor status : If estrogenreceptor positive , prior failure least 1 hormonal manipulation require unless patient premenopausal rapidly progress visceral disease No 20 % marrow involve tumor PATIENT CHARACTERISTICS : Age : 15 60 Sex : Women Menopausal status : Not specify Performance status : Karnofsky 80 % 100 % Hematopoietic : WBC least 4,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL AST le 2 time normal Albumin least 3.0 g/dL Renal : Creatinine le 1.8 mg/dL BUN le 20 mg/dL Cardiovascular : Left ventricular ejection fraction least 55 % Pulmonary : DLCO , FEV1 , FVC least 50 % predict pO2 least 70 mm Hg room air Other : No serious psychiatric , neurologic , medical illness would compromise safety bone marrow transplant Effective contraception require fertile woman PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : See Disease Characteristics Radiotherapy : No prior chest irradiation locally involved lymph node Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>